Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

A simple treatment algorithm may help reduce treatment disparities for Hispanic and Black people with multiple sclerosis (MS), according to a preliminary study released today, March 3, 2025, that will ...

Heidi Crayton, MD, and Maria Lopes, MD, discuss the most recent 2018 guidelines for multiple sclerosis treatment, emphasizing the need for updated guidelines, particularly in the payer space, to ...

For years, researchers have been hopeful they could get under the hood of multiple sclerosis. The neurological condition shows up in over 2.5 million people around the world, but it doesn’t always ...

Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, “We are pleased to share data at this year’s ACTRIMS annual meeting, including updates from the ENABLE real world study ...

Once multiple sclerosis (MS) is diagnosed (see presentation), periodic assessment of disease severity is important both for tracking disease progression (and establishing prognosis) and for monitoring ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

Advancements in MS include promising therapies like BTK inhibitors and myelin repair, evolving biomarkers, and a focus on cognition, signaling a promising future in precision medicine.

A novel program provided evidence that addressing long-known disparities in high-efficacy multiple sclerosis (MS) treatment for minority populations is a solvable problem. The program, presented by ...

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study, MS treatment ...